In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|June 5, 2018
A Closer Look at Closed System Transfer Devices
Fred Massoomi, PharmD, FASHP, senior director for Visante, discusses using closed system transfer devices.
Advertisement
Fred Massoomi, PharmD, FASHP, senior director for Visante, discusses using closed system transfer devices in creating a hazardous drug safety program, for compounding, and for administration.
Advertisement
Related to this article
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5